Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

Renee Bouwstra; Tom van Meerten; Edwin Bremer

doi:10.1080/23723556.2019.1600349

Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

Mol Cell Oncol. 2019 Apr 16;6(3):1600349. doi: 10.1080/23723556.2019.1600349. eCollection 2019.

Authors

Renee Bouwstra¹, Tom van Meerten¹, Edwin Bremer¹

Affiliation

¹ Department of Hematology, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.

Abstract

Innate immune checkpoint CD47 has emerged as a prominent target for cancer immunotherapy and defining biomarkers predictive of response will be a crucial step towards clinical implementation. Hereto, we investigated the importance of a previously reported requisite for SLAM family member 7(SLAMF7) expression on cancer cell phagocytosis for effective CD47 antibody therapy.

Keywords: CD47; DLBCL; SLAMF7; phagocytosis.

Grants and funding

Supported by grants RUG2012-5541, RUG2013-6209, RUG2014-6986, RUG2015-7887 (EB) and RUG 2014-6727 (TvM) from the Dutch Cancer Society.